Statin-induced myositis migrans

Wiener Klinische Wochenschrift

Volumn 114, Issue 21-22, 2002, Pages 943-944

  Sinzinger, Helmut ^a  

^a Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

Author keywords

Ache like symptoms; Familial hypercholesterolemia; Myositis migrans; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG INDUCED DISEASE; ELECTROMYOGRAM; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GERIATRIC PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MYALGIA; MYOSITIS; MYOSITIS NIGRANS; SYMPTOMATOLOGY;

AGED; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LOVASTATIN; MYOSITIS; PRAVASTATIN; PYRROLES; SIMVASTATIN; TIME FACTORS;

EID: 0037202845     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Biesenbach G, Janko O, Stuby U, Zazgornik J (1996) Terminales myoglobinurisches nierenversagen unter lovastatintherapie bei präexistenter chronischer nierenfunktionsstörung. Wien Klin Wochenschr 108: 334-337
2. England JDF, Walsh JC, Stewart P, et al (1995) Mitochondrial myopathy developing on treatment with the HMG CoA-reductase inhibitors - Simvastatin and pravastatin. Aust NZ J Med 25: 374-375
3. Sinzinger H, Schmid P, O'Grady J (1999) Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme A-reductase inhibitor treatment. Atherosclerosis 143: 459-460
4. Ucar M, Mjorndal T, Dahlqvist R (2000) HMG-CoA-reductase inhibitors and myotoxicity. Drug Safety 22: 441-457
5. Summary of the second report of the National Cholesterol Education Program (NCEP) (1993) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 269: 3015-3023
6. Sinzinger H, Lupattelli G, Chehne F (2000) Increased lipid peroxidation in a patient with CK elevation and muscle pain during statin therapy. Atherosclerosis 153: 255-256
7. 2α is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharmac Therapeut 26: 303-310
8. Sinzinger H, Chehne F, Lupattelli G (2002) Oxidation injury may also occur in statin-treated patients without enzyme elevation and myopathy. Drug Safety (accepted)
9. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al (2002) Clinical, pathological and biochemical features of myopathy associated with statin use. Ann Intern Med 137: 581-585
10. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR (1997) Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46: 1206-1210